Antiviral Drugs Industry 2017, Deep Market Research Report Analysis, Forecast and Outlook

Antiviral Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Antiviral Drugs Market by drug type (drugs and generic drugs), therapeutics(HIV/AIDS therapeutics, hepatitis (B&C) therapeutics, herpes therapeutics, influenza therapeutics and others) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Antiviral Drugs Market it includes the five years Industry analysis and the 6 years annual forecast from 2017 to 2023. Some of the prominent participants in the Global Antiviral Drugs Market are Roche Holding AG, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Healthcare, Med Immune/AstraZeneca, Schering-Plough, Johnson & Johnson, Merck & Co, Gilead Sciences, Dr Reddy, and Cipla. According to the report the Global Antiviral Drugs Market is projected to grow at a CAGR between 4.0 % to 4.5 % in terms of value over the period of 2017-2023.

Increasing Incidences of Epidemics in Viral Infections Such As Influenza, Respiratory Syncytial Virus and Others Anticipated To Provide Massive Growth Opportunities for this Market

Global antiviral drugs market has grown moderately over the past few years, but during the forecast period this market likely to have healthy gains. As of 2023, as per the WHO 35.3 Mn people were infected with HIV globally, hence increased in viral infection incidences considered as one of the strong driving force in this market. Due to which robust R&D activities, advanced treatments and formulations such as vaccines, combination therapy, and others introduced in the market. Moreover, Strong research and development activities have led to introduction of new drugs with better efficacy and less side effects thereby contributing significantly in the global growth. On the other hand, High risk of failure, higher cost associated with research and development activities, and stringent government regulations are the major growth barriers inhibiting global growth of this market.Increasing incidences of epidemics in viral infections such as influenza, respiratory syncytial virus and others anticipated to provide massive growth opportunities for this market over the forecast period. Whereas, High cost associated with development of new drugs and usage of natural products will pose as major challenge in front of this market.

Segments Covered:

The report segments the global antiviral drugs market by drug type, by therapeutics, by end user, and by region. The market size of each segment has been provided in terms of value (USD) and volume (tons). Market segmentation based on type includes branded drugs and generic drugs. On the basis of therapeutics global market has been divided into HIV/AIDS therapeutics, hepatitis (B&C) therapeutics, herpes therapeutics, influenza therapeutics and others (Pneumonia). Market segmentation based on end user includes hospitals, clinics, and ambulatory surgical center

US has Large Number of HIV Infected Population, Due to Which there is Vast Demand for Antiviral Drugs in this Region, and has made this Region Largest Consumer

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2017 – 2023.With over 30% global market shares in the market, North America is the largest consumer of antiviral drugs as of 2015. In which US drives the North America antiviral drugs market. Moreover US has large number of HIV infected population, due to which there is vast demand for antiviral drugs in this region, and has made this region largest consumer. Factors including high level of drug development, sophisticated healthcare infrastructure, increasing awareness level, presence of key players in this region have significantly contributed in the regional growth of North America. Following North America, Europe is the second largest market. Germany, UK, France and Italy are the important markets in this region. Asia Pacific, however, is anticipated to provide high potential growth throughout the forecast period. The region will emerge with highest CAGR on account of presence of established generic industry, growing base of target population, and improving economic stability. Furthermore, India drives the APAC antiviral therapeutics market by having highest cases of HIV.

Companies Profiled:

The companies covered in the report include Roche Holding AG, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Healthcare, Med Immune/AstraZeneca, Schering-Plough, Johnson & Johnson, Merck & Co, Gilead Sciences, Dr Reddy, and Cipla.

Table of Contents:-

1. Preface

1.1 Report Description

1.2 Research Methods

1.3 Research Approaches

2. Executive Summary

3. Global Antiviral Drugs Market Overview

3.1 Introduction

3.2 Market Dynamics

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunities

3.3 Porter’s Five Forces Analysis

3.4 IGR – Growth Matrix Analysis

3.5 Competitive Landscape in the Antiviral Drugs Market

4. Global Antiviral Drugs Market: IGR Snapshots

4.1 Global Antiviral Drugs Market key Trends

4.2 Global Antiviral Drugs Market by Application

4.3 Global Antiviral Drugs Market by Type

4.4 Global Antiviral Drugs Market by End user

4.5 Global Antiviral Drugs Market by Region

5. 1Global Antiviral Drugs by Drug Type (USD Billion) 2017 – 2023

5.1 Generic Drugs

5.2 Branded Drugs

6. Global Antiviral Drugs Market Analysis, by Therapeutics (USD Billion) 2017 – 2023

6.1 HIV/AIDS Therapeutics

6.2 Hepatitis (B & C) Therapeutics

6.3 Herpes Therapeutics

6.4 Influenza Therapeutics

6.5 Others (Pneumonia)

7. Global Antiviral Drugs Market Analysis, by End use (USD Billion) 2017 – 2023

7.1 Hospitals

7.2 Clinics

7.3 Ambulatory Surgical Centres

8. Global Antiviral Drugs Market Analysis, by Region (USD Billion) 2017 – 2023

8.1 North America

8.1.1 North America Antiviral Drugs Market by Drug Type (USD Billion

8.1.2 North America Antiviral Drugs Market by Therapeutics (USD Billion)

8.1.3 North America Antiviral Drugs Market by En user (USD Billion)

8.2 Europe

8.2.1 Europe Antiviral Drugs Market by Drug Type (USD Billion)

8.2.2 Europe Antiviral Drugs Market by Therapeutics Type (USD Billion)

8.2.3 Europe Antiviral Drugs Market by End user (USD Billion)

8.3 Asia Pacific

8.3.1 Asia Pacific Antiviral Drugs Market by drug Type (USD Billion)

8.3.2 Asia Pacific Antiviral Drugs Market by therapeutics Type (USD Billion)

8.3.3 Asia Pacific Antiviral Drugs Market by End user Channel (USD Billion)

8.4 RoW

8.4.1 RoW Antiviral Drugs Market by Drug Type (USD Billion

8.4.2 RoW Antiviral Drugs Market by Therapeutics Type (USD Billion)

8.4.3 RoW Antiviral Drugs Market by End user Channel (USD Billion)

9. Company Profiles

9.1 Roche Holding AG

9.2 GlaxoSmithKline

9.3 Bristol-Myers-Squibb

9.4 Abbott Healthcare

9.5 Med Immune/AstraZeneca

9.6 Johnson & Johnson

9.7 Merck & Co

9.8 Gilead Sciences

9.9 Cipla

9.10 Others

Click the Below Full Report:-

https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_antiviral_drugs_market



Reset Password